russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLCrussjcardiol-1843Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWРЕПЕРФУЗИЯ У БОЛЬНЫХ ОСТРЫМ ИНФАРКТОМ МИОКАРДАReperfusion in acute myocardial infarction patientsГордеевИ. Г.GordeevI. G.

кафедра госпитальной терапии №1

ИльенкоИ. В.IlyenkoI. V.

кафедра госпитальной терапии №1

КлыковЛ. Л.KlykovL. L.

кафедра госпитальной терапии №1

ЛюсовВ. А.LusovV. A.

кафедра госпитальной терапии №1

ЛебедеваА. Ю.LebedevaA. Yu.

кафедра госпитальной терапии №1

ШайдюкО. Ю.ShaydyukO. Yu.

кафедра госпитальной терапии №1

Российский государственный медицинский университетRussian Federation200628062006037175Copyright © Гордеев И.Г., Ильенко И.В., Клыков Л.Л., Люсов В.А., Лебедева А.Ю., Шайдюк О.Ю., 20062006Гордеев И.Г., Ильенко И.В., Клыков Л.Л., Люсов В.А., Лебедева А.Ю., Шайдюк О.Ю.Gordeev I.G., Ilyenko I.V., Klykov L.L., Lusov V.A., Lebedeva A.Y., Shaydyuk O.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/1843

.

.

ReferencesРуда М.Я. Что нужно знать практическому врачу о тромболитической терапии при инфаркте миокарда?//Сердце: журнал для практикующих врачей. 2002. Т. 1, № 1. C. 9-12.Руда М.Я. Что нужно знать практическому врачу о тромболитической терапии при инфаркте миокарда?//Сердце: журнал для практикующих врачей. 2002. Т. 1, № 1. C. 9-12.Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major mortality results from all randomized trials of more than 1000 patients. Lancet 1994; 343: 311-322.Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major mortality results from all randomized trials of more than 1000 patients. Lancet 1994; 343: 311-322.Максименко А.В., Тищенко Е.Г. Комбинированный тромболизис -новое направление исследование активаторов плазминогена третьего поколения//Вопросы биологической медицины и фармакологической химии. 2000. № 1. С. 1-10.Максименко А.В., Тищенко Е.Г. Комбинированный тромболизис -новое направление исследование активаторов плазминогена третьего поколения//Вопросы биологической медицины и фармакологической химии. 2000. № 1. С. 1-10.Clinical Cardiology. Bolus Fibrinolytic Therapy in Acute Myocardial infartion. JAMA 2001; 286(4).Clinical Cardiology. Bolus Fibrinolytic Therapy in Acute Myocardial infartion. JAMA 2001; 286(4).Метелица В.И. Справочник по клинической фармакологии сердечно-сосудистых лекарственных средств. 2002. С. 735.Метелица В.И. Справочник по клинической фармакологии сердечно-сосудистых лекарственных средств. 2002. С. 735.А.А. Куприна, А.А. Упницкий, Ю.Б. Белоусов. Алтеплаза: клиническая фармакология, перспективы применения при остром инфаркте миокарда, фармакоэкономические аспекты//Фарматека. 2004. № 19-20(96). С. 17-20.А.А. Куприна, А.А. Упницкий, Ю.Б. Белоусов. Алтеплаза: клиническая фармакология, перспективы применения при остром инфаркте миокарда, фармакоэкономические аспекты//Фарматека. 2004. № 19-20(96). С. 17-20.Sabatine M.S., Cannon С.Р., Gibson C.M., et al. Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infartion with ST-Segment Elevation. N. Engl. J. Med. 2005 Mar; 10: 352.Sabatine M.S., Cannon С.Р., Gibson C.M., et al. Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infartion with ST-Segment Elevation. N. Engl. J. Med. 2005 Mar; 10: 352.Mehilli J., et al. Gender and Myocardial Salvage After Reperfusion Treatment in Acute Myocardial Infarction. J. Am. Coll. Cardiol. 2005; 45: 828-31.Mehilli J., et al. Gender and Myocardial Salvage After Reperfusion Treatment in Acute Myocardial Infarction. J. Am. Coll. Cardiol. 2005; 45: 828-31.Gerschlic A.H., Stephens-Lloyd A.S., Hughes S., et al. Rescue Angioplasty after Failed Thrombolytic Therapy for Acute Myocardial Infartion. N. Engl. J. Med. 2005; 353: 2758-68.Gerschlic A.H., Stephens-Lloyd A.S., Hughes S., et al. Rescue Angioplasty after Failed Thrombolytic Therapy for Acute Myocardial Infartion. N. Engl. J. Med. 2005; 353: 2758-68.De Wood M.A., Spores J., Notske R.N., et al. Prevalence of total coronary artery occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980; 303: 897.De Wood M.A., Spores J., Notske R.N., et al. Prevalence of total coronary artery occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980; 303: 897.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected myocardial infarction: ISIS-2. Lancet 1988; 2: 349-60.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected myocardial infarction: ISIS-2. Lancet 1988; 2: 349-60.The GUSTO Angiographic Investigators. The effect of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after myocardial infarction. N. Engl. J. Med. 1993; 329: 1615-22.The GUSTO Angiographic Investigators. The effect of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after myocardial infarction. N. Engl. J. Med. 1993; 329: 1615-22.Чернецов В.А., Господаренко А.Л. Предикторы возникновения рецидивирующих расстройств кровообращения у больных крупноочаговым инфарктом миокарда после тромболитической терапии//Российский кардиологический журнал. 1999. № 6. С. 11-14.Чернецов В.А., Господаренко А.Л. Предикторы возникновения рецидивирующих расстройств кровообращения у больных крупноочаговым инфарктом миокарда после тромболитической терапии//Российский кардиологический журнал. 1999. № 6. С. 11-14.Andrews J. ST-segment recovery adds to the assessment of TIMI 2 and 3 flow in predicting infarct wall motion after thrombolytic therapy. Circulation 2000; 101: 2138, AHA.Andrews J. ST-segment recovery adds to the assessment of TIMI 2 and 3 flow in predicting infarct wall motion after thrombolytic therapy. Circulation 2000; 101: 2138, AHA.Braunwald E. Heart disease. London. WB Saunders Company; 1997. pр. 1184-1289.Braunwald E. Heart disease. London. WB Saunders Company; 1997. pр. 1184-1289.Le May M.R., Wells G.A., Labinaz M., et al. Combined Angioplasty and Pharmacological Intervention Versus Thrombolysis Alone in Acute Myocardial Infarction (CAPITAL AMI Study). J. Am. Coll. Cardiol. 2005; 46(3): 417-24.Le May M.R., Wells G.A., Labinaz M., et al. Combined Angioplasty and Pharmacological Intervention Versus Thrombolysis Alone in Acute Myocardial Infarction (CAPITAL AMI Study). J. Am. Coll. Cardiol. 2005; 46(3): 417-24.Schomig A., Mehili J., Antonicci D., et al. Mechanical Reperfusion in Patients Wth Acute Myocardial Infartion Presenting More Than 12 Hours From Symptom Onset. A Randomized Controlled Trial. JAMA 2005; 293: 2865-2872.Schomig A., Mehili J., Antonicci D., et al. Mechanical Reperfusion in Patients Wth Acute Myocardial Infartion Presenting More Than 12 Hours From Symptom Onset. A Randomized Controlled Trial. JAMA 2005; 293: 2865-2872.Fernandes-Avilas F., Alonso J.J., Castro-Beiras A., et al. Routine invasive strategy within 24 hours of thrombolysis versus ischami-aquided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial. Lancet 2004; 364: 1045-53.Fernandes-Avilas F., Alonso J.J., Castro-Beiras A., et al. Routine invasive strategy within 24 hours of thrombolysis versus ischami-aquided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial. Lancet 2004; 364: 1045-53.Yellon D.M., Baxter G.F. Protecting the ischaemic and reperfused myocardium in acute myocardial infarction: distant dream or near reality. Heart 2000; 83: 381-387.Yellon D.M., Baxter G.F. Protecting the ischaemic and reperfused myocardium in acute myocardial infarction: distant dream or near reality. Heart 2000; 83: 381-387.Kloner R.A. Does reperfusion injury exist in human? J. Am. Coll. Cardiol. 1993; 21: 537.Kloner R.A. Does reperfusion injury exist in human? J. Am. Coll. Cardiol. 1993; 21: 537.Jennings R.B., Schaper J., Hill M.L., et al. Effect of reperfusion late in the phase of reversible ischaemic injury: Changes in cell volume, electrolytes, metabolites, and ultrastructure. Circ Res 1985; 56: 262Jennings R.B., Schaper J., Hill M.L., et al. Effect of reperfusion late in the phase of reversible ischaemic injury: Changes in cell volume, electrolytes, metabolites, and ultrastructure. Circ Res 1985; 56: 262Braunwald E., Kloner R.A. Myocardial reperfusion: A double-edged sword? J. Clin. Invest. 1985; 76: 1715.Braunwald E., Kloner R.A. Myocardial reperfusion: A double-edged sword? J. Clin. Invest. 1985; 76: 1715.Ito H., Iwakura K., Oh H., et al. Temporary changes in myocardial perfusion in patients with reperfused anterior myocardial infarction. Circulation 1995; 91: 656-62.Ito H., Iwakura K., Oh H., et al. Temporary changes in myocardial perfusion in patients with reperfused anterior myocardial infarction. Circulation 1995; 91: 656-62.Ito H., Tomooka T., Sakai N., et al. Lack of myocardial perfusion immediately after successful thtombolysis: a predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation 1992; 85: 1699-705.Ito H., Tomooka T., Sakai N., et al. Lack of myocardial perfusion immediately after successful thtombolysis: a predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation 1992; 85: 1699-705.Solomon S.D., Ridker P.M., Antman E.M. Ventricular arrhythmias in trials of thrombolytic therapy for acute myocardial infarction: A meta-analysis. Circulation 1993; 88: 2575.Solomon S.D., Ridker P.M., Antman E.M. Ventricular arrhythmias in trials of thrombolytic therapy for acute myocardial infarction: A meta-analysis. Circulation 1993; 88: 2575.Vera Z., Pride H.P., Zipes D.P. Reperfusion arrhythmias: Role of early afterdepolarisations studied by monophasic action potential recordings in the infarct canine heart during autonomically denervated and stimulated sites. J. Cardiovasc. Electrophysiol. 1995; 6: 532.Vera Z., Pride H.P., Zipes D.P. Reperfusion arrhythmias: Role of early afterdepolarisations studied by monophasic action potential recordings in the infarct canine heart during autonomically denervated and stimulated sites. J. Cardiovasc. Electrophysiol. 1995; 6: 532.Дядык А.И., Багрий А.Э. Приколота О.А. и др. Желудочковые нарушения ритма при остром инфаркте миокарда. Часть 1. Эпидемиология, клиническая характеристика и прогностическая значимость. // Украинский кардиол. журн. 2001. № 3. C. 92-98.Дядык А.И., Багрий А.Э. Приколота О.А. и др. Желудочковые нарушения ритма при остром инфаркте миокарда. Часть 1. Эпидемиология, клиническая характеристика и прогностическая значимость. // Украинский кардиол. журн. 2001. № 3. C. 92-98.Chiladacis J., Karapanos G., Davlouros P. Significant of R-on T-phenomenon in early ventricular tachyarrhythmia susceptibility after acute myocardial infarction in the thrombolytic era. Am. J. Cardiology. 2000. Vol. 85, N 3. P. 289-293.Chiladacis J., Karapanos G., Davlouros P. Significant of R-on T-phenomenon in early ventricular tachyarrhythmia susceptibility after acute myocardial infarction in the thrombolytic era. Am. J. Cardiology. 2000. Vol. 85, N 3. P. 289-293.Ferrari R., Cecconi C., Curello S., Cargnoni A., et al. Occurrence of oxidative stress during myocardial reperfusion. Mol. Cell. Biochem. 1992; 111: 61-9.Ferrari R., Cecconi C., Curello S., Cargnoni A., et al. Occurrence of oxidative stress during myocardial reperfusion. Mol. Cell. Biochem. 1992; 111: 61-9.Ferrari R., Niccoli L., Vision O., Harris P. Myocardial metabolism during intracoronary thrombolysis. Int. J. Cardiol. 1987; 15: 293-9.Ferrari R., Niccoli L., Vision O., Harris P. Myocardial metabolism during intracoronary thrombolysis. Int. J. Cardiol. 1987; 15: 293-9.Jennings R.B., Hawkins H.K., Lowe J.E., Hill M.L., Klotman S., Reimer K.A. Relation between high-energy phosphate and lethal injury in myocardial ischemia in the dog. Am. J. Pathol., 1978; 92: 187-214.Jennings R.B., Hawkins H.K., Lowe J.E., Hill M.L., Klotman S., Reimer K.A. Relation between high-energy phosphate and lethal injury in myocardial ischemia in the dog. Am. J. Pathol., 1978; 92: 187-214.Rao V., Ivanov J., Weisel R.D., et al. Lactate release during reperfusion predicts low cardiac output syndrome after coronary bypass surgery. Ann. Thorac. Surg. 2001; 71: 1925-1930.Rao V., Ivanov J., Weisel R.D., et al. Lactate release during reperfusion predicts low cardiac output syndrome after coronary bypass surgery. Ann. Thorac. Surg. 2001; 71: 1925-1930.Rao V., Merante F., Weisel R.D., et al. Insulin stimulates pyruvate dehydrogenase and protects human ventricular cardiomyocytes from simulated ischaemia. J. Thorac. Cardiovasc. Surg. 1998; 116: 485-494.Rao V., Merante F., Weisel R.D., et al. Insulin stimulates pyruvate dehydrogenase and protects human ventricular cardiomyocytes from simulated ischaemia. J. Thorac. Cardiovasc. Surg. 1998; 116: 485-494.Bolli R., Jeroudi M.O., Patel B.S., et al. Direct evidence that oxygen-derived free radicals contribute to post-ischaemic myocardial dysfunction in the intact dog. Proc. Nat. Acad. Sci. USA. 1989; 86: 4695-4699.Bolli R., Jeroudi M.O., Patel B.S., et al. Direct evidence that oxygen-derived free radicals contribute to post-ischaemic myocardial dysfunction in the intact dog. Proc. Nat. Acad. Sci. USA. 1989; 86: 4695-4699.Coronary endotelial dysfunction after iscemiaand reperfusion and its prevention by iscemic preconditioning/P. Pagliaro, A. Chiribiri, D. Mancardi e.a. Ital. Heart. J. 2003. Vol. 4, N 6. P. 383-394.Coronary endotelial dysfunction after iscemiaand reperfusion and its prevention by iscemic preconditioning/P. Pagliaro, A. Chiribiri, D. Mancardi e.a. Ital. Heart. J. 2003. Vol. 4, N 6. P. 383-394.Steg P.G., Grollier G., Gallay P., et al. A randomized double-blind trial of trimetazidine as adjunctive therapy to primary PTCA for acute myocardial infarction. Evidence for improved myocardial reperfusion from ST-segment analysis. Eur. Heart. J. 1998; 19: 365 (abstract).Steg P.G., Grollier G., Gallay P., et al. A randomized double-blind trial of trimetazidine as adjunctive therapy to primary PTCA for acute myocardial infarction. Evidence for improved myocardial reperfusion from ST-segment analysis. Eur. Heart. J. 1998; 19: 365 (abstract).Gao W.D., Atar D., Liu Y., et al. Role of troponin I proteolysis in the pathogenesis of stunned myocardium. Circ. Res. 1997; 80: 393-399.Gao W.D., Atar D., Liu Y., et al. Role of troponin I proteolysis in the pathogenesis of stunned myocardium. Circ. Res. 1997; 80: 393-399.Gao W.D., Liu Y., Mellgren R., et al. Intrinsic myofilament alterations underlying the decreased contractility of stunned myocardium: a consequence of Ca2+-dependent proteolysis? Circ. Res. 1996; 78: 455-465.Gao W.D., Liu Y., Mellgren R., et al. Intrinsic myofilament alterations underlying the decreased contractility of stunned myocardium: a consequence of Ca2+-dependent proteolysis? Circ. Res. 1996; 78: 455-465.Przyklenk K. Parmacological treatment of the stunned myocardium: the concepts and the challenges. Coron. Artery. Dis. 2001; 12: 363-369.Przyklenk K. Parmacological treatment of the stunned myocardium: the concepts and the challenges. Coron. Artery. Dis. 2001; 12: 363-369.Vallance P., Chan N. Endotelial Function and nitric oxide: clinical relevance. Heart. 2001. Vol. 85, N 3. P. 342-350.Vallance P., Chan N. Endotelial Function and nitric oxide: clinical relevance. Heart. 2001. Vol. 85, N 3. P. 342-350.Granger D.N. Ischaemia-reperfusion: mechanisms of microvascular dysfunction and the influence of risk factors for cardiovascular disease. Microcirculation 1999; 6: 167-178.Granger D.N. Ischaemia-reperfusion: mechanisms of microvascular dysfunction and the influence of risk factors for cardiovascular disease. Microcirculation 1999; 6: 167-178.Pfeffer M.A. Left ventricular remodeling after acute myocardial infarction. Ann. Rev. Med. 1995; 46: 455.Pfeffer M.A. Left ventricular remodeling after acute myocardial infarction. Ann. Rev. Med. 1995; 46: 455.Klootwijk P. Noninvasive assessment of reperfusion and re-occlusion after thrombolysis in acute myocardial infarction. Am. J. Cardiol. 1993; 72: 75G-84G.Klootwijk P. Noninvasive assessment of reperfusion and re-occlusion after thrombolysis in acute myocardial infarction. Am. J. Cardiol. 1993; 72: 75G-84G.Амосова Е.Н. Метаболическая терапия повреждения миокарда, обусловленного ишемией, новый подход к лечению ишемической болезни сердца и сердечной недостаточности. // Украинский кард. журн. 2000. № 4. C. 85-92.Амосова Е.Н. Метаболическая терапия повреждения миокарда, обусловленного ишемией, новый подход к лечению ишемической болезни сердца и сердечной недостаточности. // Украинский кард. журн. 2000. № 4. C. 85-92.Б.В. Дубовик, А.А. Жданов, Д.И. Романовский. Сравнительная кардиоцитопротекторная эффективность аргинина гидрохлорида и аргинина сукцината при ишемическо-реперфузионном поражении миокарда у крыс//Бел. мед. журн. 2005. 4 (14). С. 12-16.Б.В. Дубовик, А.А. Жданов, Д.И. Романовский. Сравнительная кардиоцитопротекторная эффективность аргинина гидрохлорида и аргинина сукцината при ишемическо-реперфузионном поражении миокарда у крыс//Бел. мед. журн. 2005. 4 (14). С. 12-16.Lopaschuk G.D. Optimizing cardiac energy metabolism: a new approach to treating ischaemic heart disease//Eur. Heart. J. 1999; 1 (suppl O): 032-039.Lopaschuk G.D. Optimizing cardiac energy metabolism: a new approach to treating ischaemic heart disease//Eur. Heart. J. 1999; 1 (suppl O): 032-039.Lopaschuk G.D., Kozak R. Trimetazidine inhibits fatty acids oxidation in the heart//J. Mol. Cell. Cardiol. 1998; 30: A112.Lopaschuk G.D., Kozak R. Trimetazidine inhibits fatty acids oxidation in the heart//J. Mol. Cell. Cardiol. 1998; 30: A112.European Heart Journal (1997) 18, suppl F, F2-F10.European Heart Journal (1997) 18, suppl F, F2-F10.

The authors declare that there are no conflicts of interest present.